What were your top takeaways in SLE from ACR Convergence 2025?  

My takeaways were excitement about obintuzumab being approved, the question as to what level of proteinuria justifies biopsy, different new biomarkers regarding lupus nephritis, plus the ongoing chaos regarding CART and its spin-offs.

Enjoyed so many great talks and abstracts in advancing the care of SLE at ACR25! Some takeaways for me: The proteinuria threshold, which may identify actionable or proliferative lupus nephritis, is often lower than current practice patterns. Given the limitations of proteinuria, urinary biomarkers m...